Alpha 2.0
Login Register
» Authors » Bertrand Neveu

Bertrand Neveu

Explore the profile of Bertrand Neveu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 176
Followers 0
Related Specialties
Urology
Science
Biochemistry
Top 10 Co-Authors
Frederic Pouliot
Yves Fradet
Pallavi Jain
Lauriane Velot
Richard R Belanger
Louis Lacombe
Francois Belzile
Alain Bergeron
Audrey Champagne
Etienne Audet-Walsh
Published In
Sci Rep
Biosci Biotechnol Biochem
Prostate
J Urol
Nat Rev Urol
Affiliations
Soon will be listed here.
Recent Articles
1.
Multi-task Bayesian model combining FDG-PET/CT imaging and clinical data for interpretable high-grade prostate cancer prognosis
Larose M, Archambault L, Touma N, Brodeur R, Desroches F, Raymond N, et al.
Sci Rep . 2024 Nov; 14(1):26928. PMID: 39505979
We propose a fully automatic multi-task Bayesian model, named Bayesian Sequential Network (BSN), for predicting high-grade (Gleason   8) prostate cancer (PCa) prognosis using pre-prostatectomy FDG-PET/CT images and clinical data. BSN...
2.
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study
Pouliot F, Saad F, Rousseau E, Richard P, Zamanian A, Probst S, et al.
J Nucl Med . 2024 Sep; 65(11):1710-1717. PMID: 39327017
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to...
3.
Protocol for transducing human primary epithelial prostate cells and patient-derived organoids with high efficiency
Jobin C, Harvey M, Lacouture A, Weidmann C, Neveu B, Pouliot F, et al.
STAR Protoc . 2024 Jul; 5(3):103200. PMID: 39028619
Patient-derived organoids (PDOs) are now used to study many diseases, including prostate cancer. Here, we present a protocol for the transduction of human epithelial prostate cells and PDOs. We describe...
4.
External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high-grade prostate cancer patients
Touma N, Larose M, Ouellet J, Bedard-Tremblay D, Singbo N, Hovington H, et al.
Prostate . 2024 May; 84(12):1093-1097. PMID: 38800871
Background: Commonly used preoperative nomograms predicting clinical and pathological outcomes in prostate cancer (PCa) patients have not been yet validated in high-grade only PCa patients. Our objective is to perform...
5.
An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells
Champagne A, Chebra I, Jain P, Ringuette Goulet C, Lauzier A, Guyon A, et al.
Biosensors (Basel) . 2024 Apr; 14(4). PMID: 38667168
Prostate cancer (PCa) displays diverse intra-tumoral traits, impacting its progression and treatment outcomes. This study aimed to refine PCa cell culture conditions for dynamic monitoring of androgen receptor (AR) activity...
6.
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer
Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, et al.
Mol Oncol . 2023 Apr; 17(10):2109-2125. PMID: 37086156
The androgen receptor (AR) is an established orchestrator of cell metabolism in prostate cancer (PCa), notably by inducing an oxidative mitochondrial program. Intriguingly, AR regulates cytoplasmic isocitrate dehydrogenase 1 (IDH1),...
7.
Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy
Beck J, Rouleau M, Lemire F, Neveu B, Dery M, Theriault B, et al.
Prostate . 2023 Feb; 83(7):670-677. PMID: 36851864
Background: Androgen deprivation therapy (ADT) is the standard of care for prostate cancer treatment. Studies suggest that patients with testosterone levels below 0.7 nM have a longer time to castration...
8.
Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo
Germain L, Lafront C, Paquette V, Neveu B, Paquette J, Pouliot F, et al.
Nat Rev Urol . 2023 Feb; 20(8):480-493. PMID: 36788359
Prostate cancer is well known to be dependent on the androgen receptor (AR) for growth and survival. Thus, AR is the main pharmacological target to treat this disease. However, after...
9.
Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level
Rouleau M, Neveu B, Caron P, Morin F, Toren P, Lacombe L, et al.
J Urol . 2022 Sep; 208(6):1214-1225. PMID: 36102111
Purpose: Dihydrotestosterone and testosterone are thought to be major contributors of prostate cancer progression and resistance. We studied the modulation of 15 circulating steroids by castration and their association with...
10.
Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion
Fregeau-Proulx L, Lacouture A, Berthiaume L, Weidmann C, Harvey M, Gonthier K, et al.
Mol Metab . 2022 May; 62:101516. PMID: 35598879
Objective: The prostate is metabolically unique: it produces high levels of citrate for secretion via a truncated tricarboxylic acid (TCA) cycle to maintain male fertility. In prostate cancer (PCa), this...